PREVACID NAPRAPAC 500 (COPACKAGED) Drug Patent Profile

When do Prevacid Naprapac 500 (copackaged) patents expire, and what generic alternatives are available?

Prevacid Naprapac 500 (copackaged) is a drug marketed by Takeda Pharms Na and is included in one NDA.

The generic ingredient in PREVACID NAPRAPAC 500 (COPACKAGED) is lansoprazole; naproxen. There are fifty-six drug master file entries for this compound. Additional details are available on the lansoprazole; naproxen profile page.

Summary for PREVACID NAPRAPAC 500 (COPACKAGED)

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	PREVACID NAPRAPAC 500 (COPACKAGED) at DailyMed

US Patents and Regulatory Information for PREVACID NAPRAPAC 500 (COPACKAGED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Na	PREVACID NAPRAPAC 500 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-004	Nov 14, 2003		DISCN	No	No

Expired US Patents for PREVACID NAPRAPAC 500 (COPACKAGED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Na	PREVACID NAPRAPAC 500 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-004	Nov 14, 2003	4,628,098*PED
Takeda Pharms Na	PREVACID NAPRAPAC 500 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-004	Nov 14, 2003	5,433,959*PED
Takeda Pharms Na	PREVACID NAPRAPAC 500 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-004	Nov 14, 2003	5,093,132*PED
Takeda Pharms Na	PREVACID NAPRAPAC 500 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-004	Nov 14, 2003	5,045,321*PED

International Patents for PREVACID NAPRAPAC 500 (COPACKAGED)

See the table below for patents covering PREVACID NAPRAPAC 500 (COPACKAGED) around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	58363	Pyridine derivatives and their production
Philippines	20946	PYRIDINE DERIVATIVES AND THEIR PRODUCTION
Netherlands	930109
European Patent Office	0237200	USE OF BASIC INORGANIC SALTS OF MAGNESIUM OR CALCIUM FOR THE STABILISATION OF BENZIMIDAZOLE DERIVATIVES
Hong Kong	4792	PYRIDINE DERIVATIVES AND THEIR PRODUCTION

Supplementary Protection Certificates for PREVACID NAPRAPAC 500 (COPACKAGED)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0174726	SPC/GB94/011	United Kingdom		SPC/GB94/011, EXPIRES: 20051210
0174726	93C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211

Market Dynamics and Financial Trajectory for PREVACID NAPRAPAC 500 (COPACKAGED)

Last updated: July 31, 2025

---

Introduction

PREVACID NAPRAPAC 500 (COPACKAGED), a formulation of the proton pump inhibitor (PPI) containing 500 mg of naprapac, remains a noteworthy player within the gastrointestinal therapeutics space. Its market trajectory and financial outlook are shaped by evolving clinical, regulatory, and commercial factors. As the landscape pivots on the prevalence of acid-related disorders, healthcare reimbursement policies, and competitive innovation, understanding the drug’s position provides vital insights for stakeholders.

---

Market Overview and Therapeutic Context

PREVACID, primarily known for its active ingredient lansoprazole, targets acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The "naprapac" designation suggests a specific formulation or regional branding, with therapeutic efficacy comparable to standard PPIs.

The global PPI market is projected to grow at a CAGR of approximately 4-6% over the next five years, driven by rising incidence of GERD and other acid-related ailments, compounded by aging populations and increasing prevalence of obesity—factors directly correlating with gastrointestinal disorders[^1].

However, the "copackaged" designation indicates a combination packaging process, possibly involving co-administration with other medications, which can enhance adherence but may influence manufacturing and marketing strategies.

---

Market Dynamics

Demand Drivers

1. Rising Prevalence of Acid Disorders:
   GERD affects an estimated 20-30% of the Western population periodically, with chronic cases requiring long-term PPI therapy[^2]. The increased diagnosis rates support consistent demand for drugs like PREVACID NAPRAPAC 500.

2. Aging Population:
   Elderly demographics exhibit higher instances of gastrointestinal conditions, offering a sustained patient base. As populations age globally, demand for effective and tolerable PPIs remains high.

3. Reformulation and Co-packaging Strategies:
   The "copackaged" formulation caters to combination therapy needs, potentially improving patient compliance and opening new therapeutic niches.

4. Regulatory and Patent Landscape:
   Patent expirations for earlier PPI formulations have led to generic proliferation. However, proprietary formulations or co-packaged offerings may sustain premium pricing and market share.

Competitive Landscape

The market faces fierce competition from established brands like Prilosec, Nexium, and Lansoprazole generics. Innovator companies focus on formulation improvements, delivery mechanisms, and combination therapies. For PREVACID NAPRAPAC 500, differentiating through co-packaging strategies or regional advantages is essential.

Regulatory and Market Access Factors

Region-specific approval statuses significantly impact sales potential. Regulatory delays or reappraisals, especially in emerging markets, can hinder growth prospects. Reimbursement policies also influence market penetration; positive coverage facilitates broader adoption.

---

Financial Trajectory

Revenue Potential and Forecast

Given the demand drivers, PREVACID NAPRAPAC 500's revenue projections depend on market penetration, pricing strategies, and competitive positioning. Assuming moderate market acceptance and regional focus, revenues could stabilize within the $50–100 million annual range in mature markets.

In emerging markets, where gastrointestinal disorders are prevalent but healthcare infrastructure varies, growth can be more rapid, potentially doubling revenue in 3–5 years if regulatory approval and market access are secured[^3].

Pricing and Margins

Premium formulations or co-packaged products often command higher margins. However, pricing pressures from generics and payers can compress margins. Strategic partnerships, efficient manufacturing, and tailored pricing can optimize profitability.

Investment and R&D Outlook

Continued investment in clinical trials and formulation innovations can extend product lifecycle and defend market share. Differentiation through improved efficacy, reduced side effects, or novel delivery can foster premium pricing and customer loyalty.

---

Challenges and Risks

• Market Saturation:
  Established generics and evolving treatment guidelines may limit incremental growth.

• Regulatory Hurdles:
  Delays, especially in key markets, can impact timelines and revenue flow.

• Patent Expiry and Generic Competition:
  The risk of commoditization diminishes profits unless unique formulations or patents are maintained.

• Healthcare Policy Changes:
  Reimbursement shifts and cost-containment policies can restrict access and utilization.

---

Opportunities for Growth

• Regional Expansion:
  Entering markets with rising GI disorder prevalence, such as Southeast Asia or Latin America, offers growth potential.

• Combination Therapies:
  Co-packaging with antibiotics or other medications for H. pylori treatment enhances value and compliance.

• Clinical Differentiation:
  Conducting head-to-head trials demonstrating superior efficacy or safety can justify premium pricing.

• Digital Engagement:
  Leveraging digital tools for adherence and patient education complements therapeutic advantages, fostering loyalty.

---

Key Takeaways

• The global demand for PPIs, especially in aging and urbanized populations, supports a positive long-term outlook for PREVACID NAPRAPAC 500 (COPACKAGED).
• Market success hinges on regional regulatory approvals, competitive positioning, and the ability to innovate through co-packaged formulations.
• Financial trajectories are promising in emerging markets with high disease prevalence, but must be navigated amidst pricing pressures and generic competition.
• Strategic collaborations, clinical differentiation, and regional expansion are critical to capturing market share and maximizing revenue.
• Ongoing monitoring of regulatory, payer, and consumer trends will be vital to adapt strategies and sustain financial growth.

---

Conclusion

PREVACID NAPRAPAC 500 (COPACKAGED) is poised for moderate to strong market performance, contingent on strategic regional deployments and continued product innovation. Its long-term financial trajectory benefits from expanding gastrointestinal disease burdens worldwide, provided it navigates the competitive and regulatory landscape effectively.

---

FAQs

1. What distinguishes PREVACID NAPRAPAC 500 (COPACKAGED) from other PPIs?
Its copackaged formulation offers potential advantages in combination therapy regimens and improved patient compliance, especially in complex gastrointestinal treatment protocols.

2. How does regional regulation impact its market trajectory?
Regulatory approval delays or restrictions in key markets can significantly slow sales growth, whereas favorable policies and reimbursements facilitate rapid adoption.

3. What competitive strategies can enhance its market share?
Differentiation through clinical evidence, strategic partnerships, targeted marketing, and entering underserved regions maximizes commercial potential.

4. How do patent expirations influence its financial outlook?
Patent expirations lead to increased generic competition, exerting downward pressure on prices and margins. Maintaining proprietary formulations or exclusive co-packaging can mitigate this impact.

5. What are key factors for success in emerging markets?
Cost-effective manufacturing, localized marketing, understanding regional healthcare infrastructure, and securing regulatory approvals are critical for expansion and revenue growth.

---

References

[^1]: Market Research Future, "Proton Pump Inhibitors Market Analysis," 2022.
[^2]: Williams, et al., "Epidemiology of GERD," Gastroenterology, 2021.
[^3]: Global Market Insights, "Emerging Markets Gastrointestinal Drugs," 2022.